In Vivo Performance of Oral Liquid Formulations of Budesonide in the Fasted State in Healthy Subjects

• Status: Completed
• Trial end date: 2019-01-29
• Target enrollment: 0
• Participant gender: All

Summary

This is a single centre, open-label, sequential, single dose 4-period crossover, scintigraphic imaging study in healthy male and non-pregnant, non-lactating female subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sandoz
• Treatments: Budesonide

Criteria

Inclusion Criteria:

• Healthy males and females aged 30 to 65 years

• Body mass index 18.0 to 32.0 kg/m2

Exclusion Criteria:

• None